German Red Cross Launches First-IN-Country Study on Cerus’ INTERCEPT Blood System for Platelets
Event summary
- German Red Cross starts INITIATE study to evaluate Cerus’ INTERCEPT Blood System for pathogen-inactivated platelet concentrates in routine clinical practice.
- Study sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, first of its kind in Germany.
- Aims to assess safety profile and feasibility of broader adoption in German healthcare system.
- Non-interventional study conducted across multiple hospitals in Baden-Württemberg – Hessen and North-East regions.
The big picture
The INITIATE study marks a strategic milestone for Cerus as it seeks to expand the use of its INTERCEPT Blood System in Europe’s largest blood donation markets. With pathogen inactivation becoming a key focus for transfusion safety, this study could set a precedent for other regions grappling with similar challenges in platelet supply and infection risk management.
What we're watching
- Regulatory Alignment
- Whether the study results will accelerate adoption of pathogen inactivation in German transfusion medicine.
- Operational Feasibility
- The pace at which Cerus can demonstrate system-wide integration of INTERCEPT Blood System in routine practice.
- Market Expansion
- How this study could position Cerus for broader European adoption beyond Germany.
Related topics